SIGA Announces U.S. Government Procurement Order of $113 Million for Oral TPOXX®

Core Points - SIGA Technologies, Inc. announced a procurement option exercised by the U.S. Department of Health and Human Services for approximately $113 million of oral TPOXX® treatment courses [1][5] - This order is part of ongoing efforts to enhance orthopoxvirus preparedness and ensure public health against various threats [5] Company Overview - SIGA is a commercial-stage pharmaceutical company focused on developing innovative medicines for infectious diseases, particularly orthopoxviruses [6] - The company's flagship product, TPOXX® (tecovirimat), is approved in the U.S. and Canada for smallpox treatment and authorized in Europe and the UK for smallpox, mpox, cowpox, and vaccinia complications [6]